Abstract
Diarylsulfonylureas represent a class of antitumor agent with significant therapeutic efficacy against rodent and human models of cancer. Despite the exciting preclinical activity of sulofenur, the prototypic agent, clinical activity was poor. Here we review the activity of sulofenur and a second generation diarylsulfonylurea, LY295501 N-[5-(2, 3-dihydrobenzofuryl) sulfonyl]-N'-(3,4-dichlorophenyl)urea, against colon tumor xenografts, and some of the cellular pharmacology of this class of antitumor agents.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Benzofurans / chemistry
-
Benzofurans / therapeutic use*
-
Child
-
Clinical Trials, Phase I as Topic
-
Colonic Neoplasms / drug therapy*
-
Drug Resistance, Multiple
-
Humans
-
Phenylurea Compounds / chemistry
-
Phenylurea Compounds / therapeutic use*
-
Sulfonylurea Compounds / chemistry
-
Sulfonylurea Compounds / therapeutic use*
-
Transplantation, Heterologous
Substances
-
Antineoplastic Agents
-
Benzofurans
-
Phenylurea Compounds
-
Sulfonylurea Compounds
-
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea
-
sulofenur